Results 151 to 160 of about 360,596 (308)

Response to Oral Dapsone in a Patient With Generalised Junctional Epidermolysis Bullosa

JEADV Clinical Practice, EarlyView.
ABSTRACT Dapsone is a potent antibacterial agent used as a first‐line treatment for leprosy and employed also as an anti‐inflammatory agent. Additionally, dapsone is used for a variety of other cutaneous conditions. Herein, we report a case of intermediate junctional epidermolysis bullosa that improved significantly with oral 4,4’‐diamino‐diphenyl ...
Shiho Mori, Manabu Fujimoto, Katsuto Tamai   +2 more
wiley   +1 more source

Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis highly associated with systemic comorbidities. Accurate diagnosis and treatment remain challenging due to its rarity and clinical mimickers. Objectives To evaluate demographic, clinical features and treatment outcomes in patients referred with suspected PG at a tertiary ...
David Croitoru, Nesrine Brahimi, Haleh Zabihi, Cathryn Sibbald, Kyle Seigel, Delaram Shojaei, Eric McMullen, Afsaneh Alavi, Lily Archaempong, Aaron M. Drucker, Adam Weizman, Kenneth Croitoru, Robert Inman, Vincent Piguet   +13 more
wiley   +1 more source

Refractory postoperative eczematous dermatitis after total auricular reconstruction, temporally associated with povidone-iodine: a case report. [PDF]

Front Pediatr
Lu S, Xia X, Wang C, Zou J, Shen W.
europepmc   +1 more source

Comparing Self‐Reported and Physician‐Assessed Acne Severity Using Real‐World Data

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Real‐world data (RWD) offers access to vast amounts of health information; however, limited knowledge exists regarding its reliability in clinical and research practices. Objectives To analyse the agreement between self‐assessed severity of self‐reported acne vulgaris (AV), and physician‐assessed severity based on photographic ...
Ali Al‐Mousawi, Somaia Naassan, Misbah Noshela Ghazanfar, Sarah‐Louise Leth Kirsten, Benóný Þór Björnsson, Christian Riemer, Simon Francis Thomsen, Zarqa Ali   +7 more
wiley   +1 more source

Proteomic and experimental analyses reveal molecular signatures of flexural atopic dermatitis in antecubital and popliteal fossae and the therapeutic effect of Aida lotion. [PDF]

Front Immunol
Liu F, Li M, Gong J, Ye J, Qiu S, Xu K, Liu Q, Wu W.   +7 more
europepmc   +1 more source

Patient‐Reported Outcomes Selected by Paediatric Patients With Atopic Dermatitis in the Aiming High in Eczema/Atopic Dermatitis Approach

JEADV Clinical Practice, EarlyView.
We surveyed 290 paediatric patients with atopic dermatitis (AD)/their caregivers to determine troublesome AD features described as PROs. The most selected were itch (0‐ to 5‐year‐old children: 85%; children aged ≥ 6 years: 89.3%), skin appearance/condition (69.9% and 61.6%, respectively), and sleep disturbance (38.1% and 25.4%, respectively ...
Yuji Fujita, Sayuri Kajitani, Manabu Miyamoto, Yusuke Ando, Masaya Kato, Hironobu Fukuda, Yumi Yamada, Nozomu Kitahara, Norimasa Fukuda, Hideaki Shiraishi, Shigemi Yoshihara   +10 more
wiley   +1 more source

Dupilumab induces a significant decrease of food specific immunoglobulin E levels in pediatric atopic dermatitis patients

Clinical and Translational Allergy
Lisa P. van derRijst, Michelle S. Hilbrands, Nicolaas P. A. Zuithoff, Marjolein S. deBruin‐Weller, André C. Knulst, Thuy‐My Le, Marlies deGraaf   +6 more
doaj   +1 more source

Multidisciplinary Delphi Consensus on management of children with moderate-severe atopic dermatitis. [PDF]

Ital J Pediatr
Marseglia GL, Tosca MA, Miraglia Del Giudice M, Belloni Fortina A, Bonamonte D, Neri I, Peroni DG, D'Avino A, Comberiati P, Filippeschi C, Manti S, Galli E, Mori F, Caffarelli C, Licari A, Ciprandi G.   +15 more
europepmc   +1 more source

Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis [PDF]

, 2017
Dahdah, Lamia, Fiocchi, Alessandro, Mennini, Maurizio   +2 more
core   +1 more source

Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos, Line Kibsgaard, Trine Bertelsen   +2 more
wiley   +1 more source